Business & Finance
Oxford Biomedica signs extended deal to make AstraZeneca COVID-19 vaccine
1 July 2022 -

Gene and cell therapy company Oxford Biomedica plc (LSE:OXB) announced on Friday the signing of a new three-year agreement with pharmaceutical company AstraZeneca plc (STO:AZN) (LON:AZN) (Nasdaq:AZN).

This Master Services & Development Agreement extends an agreement that was first announced in September 2020.

The manufacture of COVID-19 vaccines at Oxford Biomedica's Oxbox facility is expected to complete in the last quarter of 2022 as part of the original commitment. Oxford Biomedica expects to record revenues of about GBP30m from the original contract in the current financial year.

Under the new agreement, manufacturing of vaccines at the Oxbox facility will be available to AstraZeneca on an as-needed basis beyond 2022.